Bioventix (BVXP)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

3,950.00p
   
  • Change Today:
      50.00p
  • 52 Week High: 4,500.00
  • 52 Week Low: 3,800.00
  • Currency: UK Pounds
  • Shares Issued: 5.21m
  • Volume: 8,977
  • Market Cap: £205.77m

Bioventix posts healthy profits, ups dividend; warns of plateauing vit-D sales

By Abigail Townsend

Date: Monday 08 Oct 2018

LONDON (ShareCast) - (Sharecast News) - Aim's Bioventix announced Monday it would pay a special dividend after a strong year of revenue and profit growth - but also sounded a warning over one of its key revenue streams.


The pharmaceutical company, which creates and supplies antibodies for use in blood testing machines, said revenues in the year to 30 June were £8.8m, a 21% increase. Pre-tax profits were ahead 19%, at £6.9m.

The cash balance was £7m, an £800,000 rise on the previous year.

The second-half dividend is 36p per share, bringing the total for the year to 61p per share. In a statement, Bioventix said it was maintaining "a cautious dividend policy that embraces continuity".

But it added: "Our current view is that a cash balance of approximately £5m is sufficient to facilitate operational and strategic agility.

"On this occasion, we have decided to distribute some surplus cash that is in excess of anticipated needs and are pleased to announce a special dividend of 55p per share."

Bioventix's most important revenue stream is from a vitamin D antibody called vitD3.5H10, which is used in vitamin D deficiency testing.

Sales of it increased 23% to £3.4m, but the company sounded a cautious note looking forward.

"Our expectation has been that, while vitamin D test volumes are increasing globally, price pressure would balance the increase in volume, leading to a relatively flat total market in US dollar terms. While actual royalties received were once again in excess of expectations we nevertheless perceive a plateauing of the vitamin D testing market."

However, the company stressed it still expected "modest growth" in vitamin D antibody sales and royalties, and pointed to growth in other core antibodies, such as testosterone, and new projects, including one to test troponin with Siemens.

Shares in Bioventix were off 5% at 150p in London at 12.30pm.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Bioventix Market Data

Currency UK Pounds
Share Price 3,950.00p
Change Today 50.00p
% Change 1.28 %
52 Week High 4,500.00
52 Week Low 3,800.00
Volume 8,977
Shares Issued 5.21m
Market Cap £205.77m

Bioventix Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average84.37% below the market average
72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average72.55% below the sector average
Price Trend
63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average63.04% below the market average
47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average47.54% below the sector average
Income Not Available
Growth
78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average78.01% above the market average
2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average2.86% above the sector average

Bioventix Dividends

  Latest Previous
  1st Interim Special
Ex-Div 08-Apr-21 29-Oct-20
Paid 23-Apr-21 13-Nov-20
Amount 43.00p 53.00p

Trades for 05-Aug-2021

Time Volume / Share Price
11:42 3,000 @ 3,851.00p
11:42 3,000 @ 3,850.00p
15:39 1,250 @ 3,880.00p
16:13 99 @ 3,925.00p
16:06 50 @ 3,920.00p

Bioventix Key Personnel

CEO Peter John Harrison
Chair Ian James Nicholson
CFO Bruce Hiscock

Top of Page